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Executive Summary
The African continent today faces a crisis of inadequate palliative care, in spite of the
growing level of suffering of its citizens who are faced with debilitating diseases and injuries. Much
of this problem stems from deeply ingrained attitudes towards opioids: while the American
continent grapples with the effects of opioid overprescribing, physicians trained in Africa are taught
that opioids are inappropriate for virtually all scenarios, and therefore they come to fear and avoid
their use or simply remain untrained on them altogether. Patients fail to advocate for themselves out
of submission to the doctor’s authority, governments remain apathetic to the situation, and as a
result thousands of Africans die every year in agonizing and completely preventable pain.
Recognizing this growing problem, American Cancer Society (ACS) has partnered with
African governments and hospice organizations to create an initiative known as “Treat the Pain.”
The main focus of the program is on in-house production of an oral morphine solution that is cheap
to make, simple to administer, and highly effective at treating pain. The program has been
implemented in 5 different African countries (Uganda, Kenya, Rwanda, Nigeria, and Swaziland), and
several other countries have expressed interest and are currently receiving “technical support” from
ACS. Due to a scarcity of high-quality data, attempts at program evaluation have been limited and it
is not known whether the initiative is having its intended effect.
This capstone represents a first attempt at utilizing the available information to determine
whether countries implementing “Treat the Pain” have indeed increased their consumption of
opioids, specifically morphine. Utilizing a United Nations report on opioid consumption, I have
attempted to determine whether there is a difference in reported morphine consumption after the
date of program implementation when compared to the years before, and also in comparison to
countries not participating in the initiative. Using a time series regression and difference-indifferences analysis, I found no statistically significant impact on morphine consumption due to
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program implementation. Given that there are few instances of the program and that the morphine
consumption data is deeply flawed, I recommend continued controlled implementation of the
program, and emphasize improved data collection going forward.
Introduction
It is difficult for those living in the developed world to imagine a scenario where a loved one
suffering with a debilitating and painful disease (such as cancer) would receive only acetaminophen
or ibuprofen as a treatment for their pain. Yet this is the daily reality for many people living in low
and middle income countries, and it reaches nearly epidemic proportions when considering the
African continent specifically. A graphical depiction of worldwide opioid consumption (in morphine
milligram equivalents per capita) in 2015 starkly reveals Africa’s anomalous behavior:
Figure 1. Worldwide Opioid Consumption, 2015

Source: https://ppsg.medicine.wisc.edu/
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When repeating this map across multiple years, a similar pattern emerges: in any given year,
different African countries might appear with a report of opioid consumption, but consistently at
very low levels. It is also consistent that each year about half of African countries fail to make a
report (i.e. “No data”).
In spite of the inexpensive nature of palliative treatment options, specifically morphine,
African governments and physicians appear irrationally averse to providing such treatment to their
patients. Yet little has been done to acknowledge or address the problem, leaving many thousands of
Africans with inadequate care. One rare exception to this tragedy has appeared in the form of a
hospice organization in partnership with American Cancer Society (ACS), creating an initiative
known as “Treat the Pain.” The concept focuses on increasing the supply of morphine, building
prescriber awareness and knowledge of palliative care, and advocating to government organizations
for improved access to pain treatments for those who are suffering.
Analysis of the program to date has been difficult (mainly due to the scarcity of quality data
on the African continent) and has focused largely on epidemiologic data to assess unmet need (ACS,
2013). It is the purpose of this capstone to determine what impact the morphine production
initiative may have had on morphine consumption in the countries where it has been implemented.
Morphine consumption data from individual countries will be analyzed in the context of the date of
ACS program implementation and compared to countries where the program has not yet been
adopted. While this analysis certainly bears flaws, its intent is to elucidate whether ACS is in fact
achieving its goal of improving morphine utilization and access, and if further expansion of the
program should be considered.
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Literature Review
The Healthcare Situation in Africa
The African continent faces a unique crisis of suffering in comparison to the rest of the
world. Perhaps its most pressing issue is an overwhelming burden of HIV/AIDS: according to
hiv.gov, 53 percent of all cases worldwide are in eastern and southern Africa (19.4 million people),
and 17 percent of cases are in western and central Africa (6.1 million people) (U.S. DHHS, 2018).
While access to antiretroviral treatment is improving through the efforts of international
organizations, those afflicted with the disease are still subject to many of its unfortunate effects.
Often overlooked are the painful side effects of AIDS, either from infection or cancer and resulting
damage to organs and tissues of the body. Also on the rise in Africa is the incidence of cancer,
which now surpasses malaria as a cause of death in Africans (635,400 cancer deaths v. 394,000
malaria deaths in 2015) (Dent et al, 2017). Cancer treatments are even less accessible than
antiretrovirals or antimalarials, meaning that the majority of cancer patients in Africa either die
before receiving treatment, or they present at advanced stages of disease when tumors are
disfiguring and extremely painful (Dent et al, 2017; Hannon, Breffni et al, 2016).
Access to palliative care services in most of Africa is similarly insufficient to meet the
overwhelming need created by AIDS, cancer, and other diseases. Palliative care refers to the range of
services employed to provide comfort and dignity to those suffering with a terminal or chronic
illness that bears a high burden of pain (WPCA and WHO, 2014). In spite of the relatively
inexpensive nature of palliative treatment options, various factors have led to the absence of such
services from much of the African continent.
Factors Influencing the Crisis
Perhaps the most apparent factor contributing to Africa’s palliative care crisis is the general
scarcity of resources throughout much of the continent. This results in deficiencies across the entire
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spectrum of healthcare, but palliative care is particularly hard hit because focusing on palliative care
does not directly improve mortality measures (i.e. palliative care is not curative) (WPCA and WHO,
2014; Knaul et al, 2018). Thus, in spite of the low cost of certain opioids, such as morphine, more
resources are directed towards other inexpensive medications such as antihypertensives, antibiotics,
antiepileptics, and antineoplastics. Meanwhile, donors to charitable organizations put emphasis on
supplying more expensive treatments such as antiretrovirals for AIDS, antimalarials, and
vaccinations (Shiffman, 2006). These organizations likewise pass over palliative care, in part because
of a lack of attention to the issue, but also out of a reluctance to supply opioids due to the
unfortunate American experience with such medications. Whereas the Western world largely
grapples with opioid overprescribing, addiction, and overdose deaths, they cannot fathom a situation
wherein increasing opioid supply might be beneficial.
The palliative care issue is not merely one of access to resources, however, but also of
attitudes towards those resources. From the government level, only 6 out of 54 countries in Africa
have a national policy on palliative care, and if official policies exist on proper handling and tracking
of controlled substances, they are either poorly defined or overly restrictive (Knaul et al, 2018;
Luyirika et al, 2016). Government disinterest is further exacerbated by international regulations
governing the ordering and tracking of controlled substances. The 1961 Single Convention on
Narcotic Drugs established an International Narcotics Control Board (INCB) that oversees the
international trade of controlled substances, such as opioids (Davis and Anderson, 2010). Individual
countries are required to submit reports to INCB of estimated needs for the coming year, and upon
review, an ordering limit is established on how much opioid or other controlled substance the
country can import or export (Davis and Anderson, 2010). In any given year, nearly half of all
African countries will either report absolutely no need for opioids or fail to report at all, meaning
that INCB will not allow them to import any opioids for the coming year (further
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appeals/negotiations are possible) (Board of Regents, 2018). It should be noted that this
phenomenon is completely unique to the African continent – in every other continent, nearly every
country indicates at least some yearly need for opioids. Yet this unusual behavior of African
governments consistently inspires little to no response either from the international community or
from within the individual countries themselves.
Such opioid-antagonistic attitudes by governments are reflective of a similar reluctance held
by prescribers and patients within these countries. Although opioids have been historically poorly
supplied as previously mentioned, the truth is that even if supply were improved the medications
would still not likely end up being prescribed to patients. This can mainly be attributed to a
phenomenon known as “opiophobia,” defined as fearful prejudice against the prescribing and use of
opioid medications, even if medically appropriate (Knaul et al, 2018). While this fear can be healthy
in the context of illicit drug use or inappropriate prescribing practices, it is inhumane and even
dangerous when there is legitimate suffering. The origins of opiophobia from the prescriber
perspective come from a lack of training on what constitutes a legitimate indication for the use of
opioids, the appropriate dosing of these drugs, or necessary monitoring parameters (Knaul et al,
2018). It is also generally true that current educational models in these nations describe opioids as
always being dangerous because of their potential to cause both addiction and life-threatening side
effects. From the patient’s perspective, a similar fear of the medication exists along with the stigma
of being viewed as an addict (Knaul et al, 2018). Culturally, the African patient is often a poor selfadvocate because the doctor is viewed as an authority figure (Knaul et al, 2018). This means that if
the doctor does not recommend treatment of pain, then it is not the patient’s responsibility to
request this of the doctor. It is also not uncommon for patients to have very little experience
interacting with doctors practicing modern medicine, and so they do not know how to handle the
encounter or what to expect from their care (Knaul et al, 2018).
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The Proposed Solution
Unique challenges such as the palliative care situation in Africa require innovative solutions,
and such an intervention has been created to address multiple problems in this crisis. Originally
conceived by a non-profit organization known as Hospice Africa Uganda (HAU) and later refined
and expanded by the American Cancer Society (ACS), the program revolves around the concept of
in-house production of oral morphine solution (Merriman and Harding, 2010). Morphine powder is
ordered from a supplier and stored offsite in a secure location. When needed, small shipments are
imported to the country and immediately mixed with water, preservative, and food coloring (to
indicate product concentration), and then distributed by trained healthcare providers (Merriman and
Harding, 2010). The end product is inexpensive, has a fairly long shelf-life, is difficult to divert, is
easy to train on administration, and, importantly, is highly effective at treating pain. In addition to
improving supply, the HAU and ACS partnership has also focused on prescriber education and
palliative care advocacy efforts, which have raised awareness of the need for palliative care services
and expanded the base of healthcare workers able to provide them (Merriman and Harding, 2010).
Methods
The goal of my capstone project is to examine the impact of an ACS-led initiative to
improve access to palliative care services (specifically morphine for treatment of pain) in various
countries in Africa. To do this, I have collected information reported to the International Narcotics
Control Board (INCB), which is an agency within the United Nations that is tasked with overseeing
imports and exports of opioids (and other controlled substances) throughout the world. Each year,
countries are expected to report estimates of national opioid consumption to the INCB in order for
the INCB to then establish yearly ordering limits.
Accessing these reports from the INCB website (www.incb.org), I collected morphine
consumption data for 55 African countries from 2007 to 2016 (the most recent report available on
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the website). Of these 55 countries, 7 were listed as having failed to report across all years, 2
countries failed to report on morphine consumption specifically, and 5 countries lacked data for
other variables in the analysis. This resulted in a total of 41 countries for my analysis. A complete
listing of included and excluded countries may be found in Appendix A.
It should be noted that there is considerable variability in how countries choose to report
opioid consumption, which requires careful consideration of the best way to handle the available
data. For example, it is very common for countries to report consumption as merely a reflection of
imports, and whatever quantity they order for the year they immediately report as “consumed.”
Given utilization and ordering patterns, it is instead more likely that a quantity of morphine ordered
in a given year may instead last several years before more must be ordered, or it may even expire
without being used at all. As previously mentioned, there are also many African countries that fail to
submit any report at all in a given year, which would technically disallow them from ordering any
opioids in that year, but to which international organizations often turn a blind eye because
utilization and ordering are so low. There are also countries that report quantities so low that the
INCB simply refers to them as “<0.5 kg,” and yet others that actually report “0 kg” of consumption
(likely an inaccurate statement but again related to the tendency to link ordering to consumption).
Because of all of these considerations, I made several decisions in my handling of the data: 1) I listed
all “<0.5 kg” reports as 0.25 kg; 2) I converted all “no reports” to 0 kg; and 3) I took 3-year averages
of opioid consumption data (e.g. “2008 morphine consumption” is the average of reported
consumption for 2007, 2008, and 2009).
After contacting ACS, I also obtained dates for when they began operations in 5 separate
countries: Uganda, Kenya, Swaziland, Nigeria, and Rwanda. Using this information, I created a
binary “yes/no” variable with “0” representing a year in which the ACS program was not present
and a “1” to represent a year in which the initiative was operational. I further learned that they have
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partial involvement in 4 other countries (Botswana, Democratic Republic of Congo, Togo, and
Benin), where they are providing “technical support” as these countries create and implement their
own palliative care initiatives. In these scenarios, ACS has offered themselves as a resource to
answer questions and give advice. In none of these 4 cases was technical support initiated prior to
2017, and so there is no direct impact on the years considered in the analysis, but it is worth noting
that there are likely some differences in morphine consumption behaviors in these countries.
Using morphine consumption as the dependent variable, I analyzed the presence of the ACS
program as the explanatory variable with the effect determined by 1) a pooled, time series regression
accounting for the fixed effects of an individual country, and 2) a difference-in-differences (diff-indiff) analysis. Other variables included in the analysis are codeine consumption, which was also
obtained from the INCB reports and converted to 3-year averages as explained above; population
data (in millions of people), as obtained from the United Nations yearly estimates on population; a
corruption perceptions index (CPI), created and published by Transparency International; and an
education index, produced by the United Nations Development Program.
Codeine Consumption
Codeine is a lower potency opioid that is internationally scheduled in a less restrictive
category than morphine or other stronger opioids. In addition to its use as a treatment for pain, it is
also commonly found in cough syrups. Because of its lower level of restriction and its multifaceted
uses, it is easily the most commonly used opioid worldwide (Davis and Anderson, 2010). In spite of
its widespread use, it is actually much more difficult than morphine to dose correctly because of
genetic variations in liver metabolism, and so it is not commonly used for treatment of severe pain
as would be the case in palliative care (Dean, 2012). I have chosen to include it in this analysis to
serve as a “baseline level” of prescribing behaviors against which to compare morphine prescribing
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behaviors (i.e. Are prescriptions for pain generally increasing throughout the country, or is morphine
alone increasing because of the effect of the initiative?).
Population Data
United Nations’ yearly population estimates were accessed from their website at
https://population.un.org/wpp/Download/Standard/Population/. Population numbers were
included because it would be expected that more populous countries would consume more
morphine. It should be noted that their report did not contain estimates for the year 2016, and so I
chose to use Microsoft Excel to estimate a population value for 2016 based off of trends.
Corruption Perceptions Index (CPI)
The Corruption Perceptions Index (CPI) was created in 1995 by an organization known as
Transparency International. Per the website, (www.transparency.org/research/cpi/overview) its goal
is to bring to light the corrupt behaviors of certain governments and thereby hold them accountable
to the international community. The index is compiled by collecting data from several surveys
distributed to various organizations (e.g. international banks, think tanks, watchdog organizations,
research groups, etc.). These surveys all contain questions dealing with the actions of governments
and their potential abuse of power. Depending on the year, there are around a dozen possible
surveys that may be completed for an individual country, although not every survey will be
completed for every country. Results are normalized to a scale of 0 to 10 (or 0 to 100, starting in
2012) and averaged, and this average comprises a country’s CPI score.
I chose to include this index (with appropriate adjustments to account for the scale change
in 2012) because the morphine consumption values reported to INCB, in addition to reflecting
prescribing behaviors, are also indicative of government awareness of palliative care and their
involvement in it. Healthcare throughout much of Africa is nationalized, so it would be reasonable
to presume that a government’s level of corruption might impact the provision of quality care to its
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citizenry. It should be noted that Swaziland did not participate in the CPI for the years 2015 and
2016, although they resumed participation in 2017 with a score of 3.9. Given that their 2014 score
was 4.3, I chose to assign 2015 and 2016 scores of 4.1 and 3.9, respectively.
Education Index
The United Nations Development Programme’s Human Development Report Office
(HDRO) calculates a yearly education index to reflect the level of education of a country’s
population. It takes into consideration both the average years of schooling of the adult population
and the expected years of schooling for children. These numbers are converted to an index by
scaling against corresponding maxima, and averaged together to form the overall education index. In
practical terms, an index score below 0.5 would suggest that, on average, adults and children are
receiving less than half the amount of education that is desirable or possible. Because morphine
consumption is also a reflection of patient attitudes toward their healthcare, I chose this index in an
effort to reflect the education of the population and thus their ability to understand and accept
treatment.
Results
This analysis was performed to compare the expected trajectory of morphine consumption
against actual consumption in countries where the ACS program was implemented. A summary of
the information used in the analysis is provided in Table 1 below.
Table 1. Summary of Data
Variable
Morphine Consumption (kg)
Codeine Consumption (kg)
Corruption Perceptions Index
Education Index
Population (millions)

Mean
Std. Dev.
Min
Max
12.6
62.6
0
573
211
701.8
0
4829
3.2
1.1
1.1
6.5
0.46
0.13
0.16
0.73
25.3
31.1
0.49
181
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Time Series Regression with Fixed Effects
Results of the time series regression are found in Table 2.
Table 2. Time Series Regression, Effects on Morphine Consumption
Variable name
Presence of ACS program
Codeine Consumption
Corruption Perceptions Index
Education Index
Population

Coefficient
P-value
95 % Conf. Interval
1.33
0.849
(-12.46 ̶ 15.13)
-0.044
<0.001
(-0.058 ̶ -0.030)
-7.04
0.050
(-14.08 ̶ -0.001)
13.97
0.842
(-123.73 ̶ 151.67)
1.96
0.001
(0.81 ̶ 3.11)

Several observations can be made from the results: First, the ACS program does not appear
to have a statistically significant effect on morphine consumption, at least as reported by the country
to the INCB, although the trend appears to be towards increased consumption. Three variables did
demonstrate statistically significant effects: codeine consumption, which actually tended to decrease
consumption of morphine (likely by substitution effect); population, where having a more populous
country would, as expected, lead to higher consumption of morphine; and having a higher
corruption perceptions index, which led to a sizeable decrease in morphine consumption.
Diff-In-Diff Analysis
In this analysis, countries not implementing the ACS program were used to form a “control
group,” indicating general trends in morphine consumption across the African continent. Countries
where the program was implemented then formed the “treatment group,” and comparisons could
then be made between pre- and post-treatment time periods (comparing treatment to control). The
results of the diff-in-diff analysis are found in Table 3.
Table 3. Diff-in-Diff Analysis, Effect on Morphine Consumption
Variable name
Presence of ACS program
Codeine Consumption
Corruption Perceptions Index

Coefficient
P-value
95 % Conf. Interval
0.39
0.956
(-13.50 ̶ 14.28)
-0.044
<0.001
(-0.058 ̶ -0.030)
-6.86
0.079
(-14.52 ̶ 0.81)
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Education Index
Population

-105.12
1.73

0.292
0.005

(-300.95 ̶ 90.72)
(0.52 ̶ 2.94)

The results are very similar to the previous time series regression, with the exception that the
effect of CPI is no longer statistically significant, and the coefficients are generally smaller in
magnitude.
Graphs of Treatment Countries
Graphical depictions of this analysis comparing the control group average to individual
treatment countries provides visual insight into a potential treatment effect. Note that for each of
the following figures, the vertical axis is scaled to the treatment country on the left side, and to the
control average on the right side. The dashed line indicates the year of ACS program
implementation. Also, the numbers depicted for morphine consumption are 3-year averages as
previously described.
Kenya
The ACS program was implemented in Kenya in 2010, and from Figure 1 there appears to
have been a significant lag effect. This could have been due to the initiative itself being in its very
early stages, and therefore requiring some time for training, facility location and preparation,
identification of target patient population, etc. It should also be noted, however that 2011-2014 were
all “no report” years for Kenya, after which a very large quantity was reported in 2015 (potentially a
“catch-up” report accounting for several years of missing data?). It would be interesting to see if this
trend of increased consumption continued in subsequent years, but the latest available data on the
INCB website is from 2016.
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Figure 1. Kenya vs Control

Annual Morphine Consumption (kg)

35

20
18

30

16
25

14
12

20

10
15

8
6

10
Kenya
5
0

4

Control Avg

2008

2009

2010

2011

2012

2013

2014

2015

2
0

Year

Nigeria
Nigeria officially partnered with ACS beginning in 2012, and as depicted in Figure 2, there
appears to have been an initial surge in consumption. This effect tapers off in 2015, however,
blunting the overall post-treatment effect and calling into question the sustainability of the initiative.
It should be noted that Nigeria is Africa’s most populous country, so these morphine consumption
numbers being well below the continent’s average is discouraging and are most certainly insufficient
to meet needs.
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Figure 2. Nigeria vs Control
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Rwanda
Rwanda implemented the ACS program during 2011 and seems to have experienced a lag in
program implementation, similar to Kenya, as depicted in Figure 3. Unlike Kenya and Nigeria,
however, the effect does not appear to reach a saturation point and consumption grows throughout
the time period in question. It should be noted that, from the national level, Rwanda also became
the first African country to establish a national policy on palliative care in 2011 (Krakauer et al,
2018). This underscores the importance of government involvement in achieving success with the
ACS initiative, particularly when healthcare is run from the national level.
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Annual Morphine Consumption (kg)

Figure 3. Rwanda vs Control
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Swaziland
The ACS initiative was implemented in Swaziland starting in 2012, and as depicted in Figure
4, it appears to have had an impact from the start. Prior to program implementation, Swaziland had
never submitted a report to the INCB, and in reality did not start submitting reports until 2014
(again, likely a “catch-up” report). Because of this, it is difficult to actually gauge the effect in early
years of program implementation, but it does appear to have eventually reached the level of affecting
government reporting.
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Figure 4. Swaziland vs Control
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Uganda
Uganda represents the most problematic country to analyze, because in actuality it was the
country that pioneered the oral morphine solution approach, as early as 1993 (Merriman and
Harding, 2010). It should be noted that before 2010, Uganda was already consuming morphine at
relatively high levels, and so ACS involvement probably served more to bolster already existing
resources and infrastructure. This seems to be verified by the appearance of Uganda’s morphine
consumption in Figure 5, which fluctuates but generally stays around 17 kg. Bearing this theory in
mind, I chose to repeat the previous analyses (time series regression and diff-in-diff analysis)
utilizing all of the same data but with Uganda excluded. The results are seen in Tables 4 and 5.
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Figure 5. Uganda vs Control
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Table 4. Time Series Regression with Uganda Excluded
Variable name
Presence of ACS program
Codeine Consumption
Corruption Perceptions Index
Education Index
Population

Coefficient
P-value
95 % Conf. Interval
5.08
0.514
(-10.22 ̶ 20.38)
-0.045
<0.001
(-0.059 ̶ -0.030)
-7.76
0.035
(-14.95 ̶ -0.56)
15.90
0.823
(-123.57 ̶ 155.37)
2.01
0.001
(0.83 ̶ 3.18)

Table 5. Diff-in-Diff Analysis with Uganda Excluded
Variable name
Presence of ACS program
Codeine Consumption
Corruption Perceptions Index
Education Index
Population

Coefficient
P-value
95 % Conf. Interval
5.09
0.515
(-10.27 ̶ 20.44)
-0.045
<0.001
(-0.060 ̶ -0.031)
-7.81
0.051
(-15.63 ̶ 0.02)
-118.16
0.245
(-317.88 ̶ 81.56)
1.74
0.005
(0.52 ̶ 2.97)
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The results of this analysis seem to confirm that Uganda was influencing the ability to
observe a treatment effect. While the ACS program is still not demonstrating a statistically
significant effect, the p-value is much lower than in the previous analyses and the coefficient is much
greater in magnitude.
Discussion
Assessing the Analysis
Although the ACS program did not appear to demonstrate statistical significance with the
data available, it is worth discussing what may have prevented such an outcome. One potential
problem is the small number of instances of program implementation: Of the 41 countries included
in the analysis, only 5 of them (12.2%) fully implemented the program, and for a total of only 30
years of demonstrated experience out of a possible 410 years (7.3%). From among the treatment
countries, Uganda presents an interesting case to analyze for the fact that it had a primitive version
of the ACS program prior to 2010. It is very possible that 2010 represented less of a change and
more of a bolstering of the program already in place. Indeed, looking at the graph of Uganda’s
morphine consumption, it would appear to be in more of a plateau phase than an upward slope.
This likely diminished the observed effect of program implementation. Removing Uganda from the
equation does noticeably change the results, but accentuates the problem of having too few
instances of program implementation by narrowing the treatment countries to four. Additionally, it
is difficult to account for the countries partially implementing the program (Benin, Botswana, DRC,
Togo) by receiving technical assistance from ACS.
The idea of a treatment and control group in this particular analysis is also somewhat of a
flawed concept. In speaking with individuals at ACS, there was a calculated process involved in
choosing some of the initial countries where the program was implemented. Generally speaking,
they selected countries with relative stability, cooperative governments, and a willingness to
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implement the program, indicating a mentality already primed for program implementation. In other
words, the treatment group was not by any means randomly selected, and there are likely inherent
differences between treatment and control countries. I attempted to account for this by including
the CPI variable and including regionally similar countries in the analysis, but it should be noted that
this is far from a randomized experiment.
All things considered, the most significant weakness in this analysis lies in the morphine
consumption data itself. As mentioned previously, there is substantial variability in how the data is
reported, resulting in a lack of confidence that the numbers in the report accurately reflect
consumption. The potential bias resulting from countries failing to report anything presented a
considerable challenge because of not knowing how to treat the information. The intended purpose
in the creation of INCB was to prevent abuse and diversion of controlled substances, and in
countries where use is so low (as is the case in much of Africa) the organization tends to take a
hands off approach, allowing the countries to import their small quantities of opioids but without
close supervision. As a result, accountability for data reporting is extremely low and consequences
for a failure to report are non-existent. In all there were 126 incidences of a failure to report out of a
possible 410 opportunities to report. Countries failing to report across the entire 10 years observed
were, of necessity, excluded from the dataset, but this again potentially introduces bias into the
analysis.
All of this led me to the calculation of 3-year consumption averages to better reflect what I
believe may actually be occurring. However, this choice also likely diluted out the effect of any
sudden spike in opioid consumption at the time of program implementation. Ideally, more robust
consumption data would be required to obtain a high-confidence analysis and result, such as
compiled prescription data from physician practice sites or hospice programs. Considering that the
focus of this initiative is on improving palliative care, what would be even more useful would be
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knowledge of the diagnoses for which an opioid is being prescribed, a count of untreated cases of
painful suffering, and quantification of opioid use not related to surgery or childbirth. As medical
data systems advance and improve in Africa, it will be increasingly important to include such
opportunities for data collection to better assess quality of care and outcomes.
This problem with the unavailability of high-quality data is a frustration for researchers in
many parts of the world, but it is particularly apparent in the context of African research. Ideally for
this analysis, I would have liked to include some measure of disease burden to represent the need for
palliative care, which I believe would influence the amount of morphine consumption. When
searching through published data, however, I quickly discovered that there is simply no information
being collected or reported throughout the vast majority of the African continent. A yearly
publication known as GLOBOCAN reports the incidence of cancer for countries around the world,
but they readily admit that there is simply no data available for nearly all of Africa – in 2012, there
were only 2 countries (Egypt and South Africa) with any cancer data to speak of (Ferlay et al, 2015).
Much of this problem stems from the lack of access to care, or a lack of effort to access the care that
is available, and therefore many cases of disease go undiagnosed. It would also appear, however, that
even in cases where care is administered, there is a lack of detailed documentation of the encounter.
This sort of information will be key to Africa’s ability to recognize and address problems such as this
crisis of palliative care that would otherwise go undetected.
The Effect of South Africa
It is worth noting the impact of South Africa on this analysis. As noted in Table 1 in which
the data is summarized, the average morphine consumption for the continent is around 12 kg per
year. Table 1 further reveals that the maximum value for morphine consumption was 573 kg, which
occurred in South Africa in 2011 (note that this is actually a value based on a 3 year average – the
actual number reported to INCB that year was 962 kg, but which was diluted out by lower numbers
Page | 21

in 2010 and 2012). Compared to the other countries in the analysis, South Africa is an extreme
outlier, which strongly impacted the shape of the curve for the control group, as depicted in Figure 6
(note the extreme differences in scale of the vertical axis between the control average and South
Africa’s consumption).
Figure 6. Comparison of South Africa and Control Group
20

700

Annual Morphine Consumption (kg)

18

600

16
500

14
12

400

10
300

8
6

200

4

Avg all

2

South Africa

0

2008

2009

2010

2011

2012

2013

2014

100
0

2015

Year

When South Africa is excluded from the control group, the shape of the curve changes
dramatically both in magnitude and shape, as depicted in Figure 7, and a summary of the data
without South Africa reveals a changed dataset in terms of opioid consumption (Table 6).
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Figure 7. Control Averages, with and without South Africa
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Table 6. Summary of Dataset without South Africa
Variable
Morphine Consumption (kg)
Codeine Consumption (kg)
Corruption Perceptions Index
Education Index
Population (millions)

Mean
Std. Dev.
Min
Max
3.2
6.8
0
48.7
121
400.3
0
2980
3.2
1.1
1.1
6.5
0.45
0.12
0.16
0.73
24.6
31.2
0.49
181

It was my desire to remove South Africa from the analysis altogether, but doing so presented
several problems in and of itself. In terms of its consumption behavior, South Africa more strongly
resembles European levels, and of all of the countries in the analysis, its data is the most believable

Page | 23

and likely the most accurate. Removing South Africa from the dataset accentuates the problem of
having far too many countries with poor reporting. Furthermore, it leaves mostly countries with very
low levels of consumption, making changes in consumption trends more nuanced and difficult to
observe. These concerns were verified in my attempts to perform analyses without South Africa,
which left virtually every variable as statistically insignificant, as shown in Table 7.
Table 7. Time Series Regression, without South Africa
Variable name
Presence of ACS program
Codeine Consumption
Corruption Perceptions Index
Education Index
Population

Coefficient
P-value
95 % Conf. Interval
-0.044
0.980
(-3.49 ̶ 3.40)
-0.003
0.281
(-0.007 ̶ 0.002)
0.36
0.666
(-1.27 ̶ 1.99)
-18.56
0.244
(-49.88 ̶ 12.76)
0.63
<0.001
(0.35 ̶ 0.91)

I chose to include South Africa mainly because of the quality of the data it provided. While I
acknowledge that it strongly influenced the outcome, I am somewhat reassured by a careful
comparison of the different averages depicted in Figure 7. In general, the trends are at least similar:
the lowest point is in 2008, and there is a local maximum in 2011, a local minimum in 2013, and an
upward trend in 2014 through 2015.
Recommendations and Future Directions
The results of this research do not allow me to confidently recommend the program for
widespread implementation. In no case did this concept spiral out of control or result in systemic
overuse or misuse of morphine. Thus the risk of harm appears to be minimal, particularly in the
African context, where opioids are so woefully underutilized. There are currently too few instances
to truly gauge the full effect of the program, and therefore it is worth further experimentation to
observe possible outcomes. As previously mentioned, improved data collection and reporting will be
important going forward.
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From my research on this situation, I believe that the most significant roadblock to
improving palliative care in Africa exists with the doctors themselves. While my experiment was
limited to available data and focused more on a measurement of program outputs (i.e. morphine
consumption), I feel that it would be more useful to determine program outcomes. Specifically, is
the training being administered by the ACS program having an impact on prescriber attitudes and
behaviors? This could be achieved by administering a survey to program participants, both prior to
training to determine baseline attitudes and upon completion of the program. The survey should
gauge attitudes toward opioids, knowledge of situations where it is appropriate to prescribe them,
knowledge of how to dose them, and knowledge of necessary monitoring parameters. This is
important because no matter how much morphine supply is increased, it will not have an impact
unless prescribers are willing to utilize what is made available.
It is also important to determine government attitudes towards palliative care. The majority
of African countries administer healthcare from the national level, and much of the healthcare
provided is driven by standard treatment guidelines (STGs) which essentially serve as treatment
protocols describing how to respond to a particular clinical scenario. An interesting topic of study
would be to determine how many countries in Africa have an established palliative care STG that
includes morphine for the treatment of severe pain.
A great deal of work remains to be done in regards to this crisis. This capstone paper
represents a first attempt at program evaluation and hopefully serves to shed light on an
unacceptable situation that merits immediate attention. This is a humanitarian catastrophe that has
led to unnecessary suffering for many thousands, if not millions, of Africans who are left to die
ignominious deaths. The resources exist to rectify this situation in an affordable manner, but it will
require the concerted efforts of international organizations, governments, and healthcare providers
to adequately address the problem.
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Appendix A
Countries included in the analysis:
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Chad
Congo, Democratic Republic of
Cote d’Ivoire
Egypt
Eritrea
Ethiopia
Gabon
Ghana
Kenya*
Lesotho
Libya
Madagascar
Malawi

Mali
Mauritania
Mauritius
Morocco
Mozambique
Namibia
Niger
Nigeria*
Rwanda*
Senegal
Sierra Leone
South Africa
Sudan
Swaziland*
Tanzania
Togo
Tunisia
Uganda*
Zambia
Zimbabwe

* - Indicates a treatment country
Countries excluded from the analysis:
•
•
•

Due to a failure to report across all years of the analysis (2007-2016):
o Central African Republic, Djibouti, Equatorial Guinea, Gambia, Republic of Congo,
Somalia, South Sudan
Due to a failure to report morphine consumption across all years of the analysis (2007-2016):
o Guinea, Liberia
Due to an inability to obtain other data for the analysis:
o Ascension Island, Saint Helena, Sao Tome and Principe, Seychelles, Tristan da
Cunha
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